EDSA

Edesa Biotech Inc

2.67

Oct 15 • 3:59 PM ET +0.02 (0.75%)

2.67

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Canada Nano NASD

Today, 9:50 AMEdesa Biotech announces FDA clearance of IND for Phase 2 U.S. study of EB06 in vitiligo

Peers: ALPS SPRO VRCA CNTB GALT GNLX IMUX IPHA KZIA AGEN

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	36.08M
Enterprise Value	34.16M
Income	-14.10M
Sales	0.00M
Book/sh	0.04
Cash/sh	0.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Jun 21, 2010

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	64.46
P/C	3.49
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.76
Current Ratio	2.76
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.69
EPS next Y	-2.07
EPS next Q	-0.58
EPS this Y	-56.43%
EPS next Y	-4.03%
EPS next 5Y	-17.31%
EPS past 3/5Y	-6.32% -11.35%
Sales past 3/5Y	- -
EPS Y/Y TTM	-27.34%
Sales Y/Y TTM	-
EPS Q/Q	-140.99%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-37.93% -

Insider Own	18.88%
Insider Trans	0.00%
Inst Own	37.97%
Inst Trans	7.53%
ROA	-102.46%
ROE	-122.93%
ROIC	-160.05%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-27.27%
SMA50	-38.83%
SMA200	-52.25%
Trades

Shs Outstand	13.51M
Shs Float	10.96M
Short Float	1.86%
Short Ratio	3.26
Short Interest	0.20M
52W High	20.32 -86.86%
52W Low	0.72 270.83%
Volatility	11.95% 8.50%
ATR (14)	0.34
RSI (14)	26.26
Beta	1.21
Rel Volume	1.22
Avg Volume	62.40K
Volume	75,822

Perf Week	-27.05%
Perf Month	-31.01%
Perf Quarter	-59.55%
Perf Half Y	-48.05%
Perf YTD	88.03%
Perf Year	5.12%
Perf 3Y	-32.49%
Perf 5Y	-95.12%
Perf 10Y	-99.58%
Recom	1.00
Target Price	16.33
Prev Close	2.65
Price	2.67
Change %	0.75%

Today 09:15AM	Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study (GlobeNewswire)
Aug-19-26 10:20PM	Edesa Biotech Announces Pricing of $25.0 Million Public Offering (GlobeNewswire) -17.22%
04:01PM	Edesa Biotech Announces Proposed Public Offering (GlobeNewswire)
Aug-13-26 04:15PM	Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results (GlobeNewswire)
Jun-11-26 09:15AM	Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors (GlobeNewswire) +8.45%
09:20AM	Loading…
Jun-05-26 09:20AM	Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury (GlobeNewswire) -22.99%
May-19-26 09:15AM	Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference (GlobeNewswire) +32.78%
May-14-26 04:30PM	Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results (GlobeNewswire) -10.68%
Mar-31-26 04:20PM	Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit (GlobeNewswire) +6.12%
Mar-26-26 09:15AM	Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment (GlobeNewswire) -10.81%
Feb-24-26 09:15AM	Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study (GlobeNewswire) +67.96%
Feb-13-26 04:20PM	Edesa Biotech Reports Fiscal 1st Quarter 2026 Results (GlobeNewswire)
Dec-12-25 04:20PM	Edesa Biotech Reports Fiscal Year 2025 Results (GlobeNewswire) -16.09%
Oct-31-25 04:30PM	Edesa Biotech Announces Upcoming Conference Schedule (GlobeNewswire) -6.45%
Oct-28-25 07:45AM	Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study (GlobeNewswire) -17.87%
04:35PM	Loading…
Aug-08-25 04:35PM	Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results (GlobeNewswire)
May-14-25 04:15PM	Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results (GlobeNewswire)
Apr-28-25 04:30PM	Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference (GlobeNewswire)
Apr-04-25 04:15PM	Edesa Biotech Announces Chief Financial Officer Transition (GlobeNewswire) -5.63%
Feb-14-25 04:15PM	Edesa Biotech Reports Fiscal 1st Quarter 2025 Results (GlobeNewswire) -17.23% -7.06%
Feb-13-25 07:00AM	Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +74.73%
Dec-13-24 04:30PM	Edesa Biotech Reports Fiscal Year 2024 Results (GlobeNewswire) +7.56%
Oct-31-24 08:15AM	Edesa Biotech's Founder Makes Strategic Investment in the Company (GlobeNewswire)
Oct-21-24 08:15AM	Edesa Biotech Announces Upcoming Conference Schedule (GlobeNewswire) -5.83%
Aug-09-24 09:53PM	EDSA Stock Earnings: Edesa Biotech Beats EPS for Q3 2024 (InvestorPlace) -5.46%
04:20PM	Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results (GlobeNewswire)
Jun-24-24 08:20AM	BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS (ACCESSWIRE)
May-10-24 08:53PM	EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024 (InvestorPlace)
04:15PM	Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results (ACCESSWIRE)
Apr-11-24 09:00AM	Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference (ACCESSWIRE)
09:00AM	Loading…
Apr-02-24 09:00AM	Edesa Biotech to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Mar-21-24 04:30PM	Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference (ACCESSWIRE) -5.32%
Mar-07-24 08:45AM	Edesa Biotech to Participate in Barclays Global Healthcare Conference (ACCESSWIRE)
Mar-04-24 04:30PM	Edesa Biotech to Participate in Upcoming Dermatology Meetings (ACCESSWIRE) -5.41%
Feb-09-24 04:15PM	Edesa Biotech Reports Fiscal 1st Quarter 2024 Results (ACCESSWIRE) +7.87%
Jan-04-24 04:15PM	Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week (ACCESSWIRE)
Dec-18-23 05:51AM	EDSA Stock Earnings: Edesa Biotech Beats EPS for Q4 2023 (InvestorPlace) -7.51%
Dec-15-23 04:10PM	Edesa Biotech Reports Fiscal Year 2023 Results (ACCESSWIRE)
Nov-20-23 04:05PM	Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study (ACCESSWIRE) -8.20%
Oct-26-23 04:05PM	Edesa Biotech to Present at Dermatology Drug Development Summit (ACCESSWIRE)
Oct-25-23 09:10AM	Regulators Approve Updated Phase 3 Trial Design for Edesa Biotechs ARDS Drug (ACCESSWIRE)
Oct-19-23 09:15AM	EDSA: Secures up to CAD$23 Million to Fund Development of EB05 (Zacks) -9.76%
Oct-12-23 12:15PM	Edesa Biotech Secures $10 Million Credit Facility with Company Founder (ACCESSWIRE) +80.74%
12:10PM	Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government (ACCESSWIRE)
Oct-10-23 09:00AM	Edesa Biotech Announces One-for-Seven Reverse Share Split (ACCESSWIRE) -32.69%
Sep-28-23 08:15AM	Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate (ACCESSWIRE) -8.66%
Aug-16-23 11:40AM	EDSA: EB05 Inhibits Inflammation Initiated by Multiple Pathogens In Vitro (Zacks)
Aug-09-23 04:15PM	Edesa Biotech Reports Fiscal Third Quarter 2023 Results (ACCESSWIRE)
Aug-04-23 08:56AM	Companies Like Edesa Biotech (NASDAQ:EDSA) Could Be Quite Risky (Simply Wall St.) -11.10%
Jul-26-23 09:00AM	Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference (ACCESSWIRE)
Jun-28-23 03:55PM	Edesa Biotech's COVID-19 Candidate Restraints Inflammation From Influenza, Other Pathogens In Preclinical Studies (Benzinga)
07:55AM	Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens (ACCESSWIRE)
Jun-27-23 08:15AM	Edesa Biotech Appoints Biotech Deal Veteran to CFO Role (ACCESSWIRE)
Jun-15-23 08:00AM	Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name (ACCESSWIRE)
May-17-23 08:22AM	EDSA: FDA Agrees on Primary Endpoint for Phase 3 ARDS Drug Study (Zacks Small Cap Research) +10.59%
May-11-23 04:30PM	Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results (ACCESSWIRE) -6.68%
Apr-20-23 08:30AM	Edesa Biotech to Participate in Swiss Biotech Day (ACCESSWIRE)
Apr-04-23 08:45AM	The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate (ACCESSWIRE)
Mar-23-23 04:30PM	Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference (ACCESSWIRE)
Mar-16-23 04:10PM	Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting (ACCESSWIRE) -19.15%
Mar-15-23 08:10AM	Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study (ACCESSWIRE)
Feb-15-23 05:11AM	EDSA: Positive News Flow to Start 2023 (Zacks Small Cap Research)
Feb-12-23 09:00AM	Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Invest In Growth? (Simply Wall St.)
Feb-10-23 09:00AM	Edesa Biotech Reports Fiscal 1st Quarter 2023 Results (ACCESSWIRE)
Feb-01-23 08:15AM	Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study (ACCESSWIRE) -6.00%
Jan-18-23 05:50AM	EDSA: 1.0% EB01 Cream Achieves Primary Endpoint in Phase 2b Trial (Zacks Small Cap Research)
Jan-17-23 12:30PM	Edesa Biotech's Dermatitis Study Data Fails To Cheer Investors (Benzinga) -42.06%
08:30AM	Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug (ACCESSWIRE)
Dec-22-22 06:47AM	EDSA: Phase 2b Data for EB01 Anticipated in January 2023 (Zacks Small Cap Research) +36.50%
Dec-20-22 08:30AM	FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate (ACCESSWIRE) +17.37%
Dec-16-22 09:00AM	Edesa Biotech Reports Fiscal Year 2022 Results (ACCESSWIRE)
Dec-02-22 08:00AM	Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference (ACCESSWIRE)
Nov-03-22 09:00AM	Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market (ACCESSWIRE)
Oct-03-22 11:10AM	EDSA: Statistically Significant Mortality Reduction in Phase 2 ARDS Trial (Zacks Small Cap Research) +19.40%
Sep-30-22 08:00AM	Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study (ACCESSWIRE) -35.12%
Sep-08-22 04:30PM	Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference (ACCESSWIRE)
Sep-07-22 08:00AM	Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment (ACCESSWIRE)
Aug-24-22 07:15AM	EDSA: Phase 3 ARDS Study Expanded to Include Mechanically Ventilated Patients (Zacks Small Cap Research)
Aug-12-22 04:30PM	Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results (ACCESSWIRE)
Aug-03-22 08:15AM	Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference (ACCESSWIRE)
Jul-16-22 08:11AM	Edesa Biotech, Inc. (NASDAQ:EDSA): Are Analysts Optimistic? (Simply Wall St.)
Jul-11-22 08:30AM	Edesa Biotech to Present at ARDS Drug Development Summit (ACCESSWIRE)
May-24-22 01:04PM	Edesa Biotech Adds Mechanically Ventilated Patients To Late-Stage COVID-19 Study (Benzinga) -6.42%
07:55AM	Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study (ACCESSWIRE)
May-19-22 04:30PM	Edesa Biotech to Present at H.C. Wainwright Global Investment Conference (ACCESSWIRE)
10:12AM	EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22 (Zacks Small Cap Research)
May-17-22 08:43AM	Here's Why We're Not At All Concerned With Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation (Simply Wall St.) +5.98%
May-13-22 08:55AM	Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results (ACCESSWIRE)
Apr-28-22 07:45AM	Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected (ACCESSWIRE)
Mar-29-22 09:00AM	Edesa Biotech Appoints Strategy Expert to Board of Directors (ACCESSWIRE)
Mar-24-22 04:30PM	Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering (ACCESSWIRE)
Mar-22-22 08:00AM	Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -13.11%
Feb-18-22 07:05AM	EDSA: Phase 3 Trial of EB05 Hits 25% Enrollment (Zacks Small Cap Research) -5.88%
Feb-17-22 08:00AM	Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study (ACCESSWIRE)
Feb-14-22 09:00AM	Edesa Biotech Reports Fiscal 1st Quarter 2022 Results (ACCESSWIRE)
Feb-06-22 07:42AM	When Can We Expect A Profit From Edesa Biotech, Inc. (NASDAQ:EDSA)? (Simply Wall St.)
Jan-26-22 07:45AM	Edesa Biotech to Join Ontario Bioscience Panel Discussion (ACCESSWIRE)
Jan-13-22 09:55AM	Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy (Benzinga) -8.29%
07:55AM	Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy (ACCESSWIRE)
Jan-06-22 05:28AM	EDSA: Important Inflection Points Likely in 2022 (Zacks Small Cap Research)

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

M.D.Dr. Pardeep Nijhawan FRCPC

Ph.D.Dr. Michael J. Brooks M.B.A.

M.Sc.Mr. Peter John Weiler M.B.A

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brooks Michael J	President	Feb 26 '26	Buy	1.57	2,000	3,140	226,870	Mar 11 05:02 PM
Nijhawan Pardeep	Chief Executive Officer	Mar 10 '26	Buy	6.60	1,000	6,599	628,813	Mar 10 05:02 PM
Nijhawan Pardeep	Chief Executive Officer	Mar 05 '26	Buy	3.90	10,000	39,000	402,702	Mar 06 05:01 PM
Nijhawan Pardeep	Chief Executive Officer	Mar 04 '26	Buy	4.26	10,000	42,560	392,702	Mar 05 05:01 PM
Nijhawan Pardeep	Chief Executive Officer	Mar 03 '26	Buy	3.63	10,000	36,300	382,702	Mar 04 05:01 PM
Nijhawan Pardeep	Chief Executive Officer	Mar 02 '26	Buy	2.00	2,000	4,000	627,813	Mar 03 05:00 PM
Nijhawan Pardeep	Chief Executive Officer	Mar 02 '26	Buy	2.28	1,000	2,280	372,702	Mar 03 05:00 PM
Nijhawan Pardeep	Chief Executive Officer	Feb 27 '26	Buy	2.22	30,000	66,696	371,702	Mar 02 05:05 PM
Nijhawan Pardeep	Chief Executive Officer	Feb 26 '26	Buy	1.58	20,571	32,480	615,797	Mar 02 05:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EDSA

Edesa Biotech Inc

Upgrade your Finviz experience